燃石醫學(BNR.US)一季度營收1.256億元,預計全年將實現盈虧平衡
格隆匯5月29日丨燃石醫學(BNR.US)公佈2024年一季度的財務報吿。財報顯示,公司2024年一季度總營收為人民幣1.256億元,同比下降11.9%。其中,醫院內業務的收入為人民幣5740萬元,同比增長11.3%;中心實驗室業務的收入為人民幣4760萬元,同比下降23.0%;藥物研發服務的收入為人民幣2060萬元,同比下降29.3%。一季度毛利為人民幣8570萬元,同比下降13.2%。非美國通用會計準則下,一季度毛利為9300萬元,同比下降13.8%,毛利率為74%。第一季度淨虧損為人民幣1.215億元。
截至2024年3月31日,現金、現金等價物、受限制現金以及短期投資總額為人民幣5.727億元。
公司預計2024年全年將實現盈虧平衡(以非美國通用會計準則毛利潤減去非美國通用會計準則銷售、一般及行政費用計算)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.